AU2022223701A1 - Remittive effects of tapinarof in the treatment of plaque psoriasis, atopic dermatitis, or radiation dermatitis - Google Patents

Remittive effects of tapinarof in the treatment of plaque psoriasis, atopic dermatitis, or radiation dermatitis Download PDF

Info

Publication number
AU2022223701A1
AU2022223701A1 AU2022223701A AU2022223701A AU2022223701A1 AU 2022223701 A1 AU2022223701 A1 AU 2022223701A1 AU 2022223701 A AU2022223701 A AU 2022223701A AU 2022223701 A AU2022223701 A AU 2022223701A AU 2022223701 A1 AU2022223701 A1 AU 2022223701A1
Authority
AU
Australia
Prior art keywords
weeks
subject
tapinarof
study drug
week
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022223701A
Other languages
English (en)
Inventor
Kimberly Ann MCHALE
Stephen C. PISCITELLI
David Scott Rubenstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dermavant Sciences GmbH
Original Assignee
Dermavant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermavant Sciences GmbH filed Critical Dermavant Sciences GmbH
Publication of AU2022223701A1 publication Critical patent/AU2022223701A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022223701A 2021-02-17 2022-02-17 Remittive effects of tapinarof in the treatment of plaque psoriasis, atopic dermatitis, or radiation dermatitis Pending AU2022223701A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163150204P 2021-02-17 2021-02-17
US63/150,204 2021-02-17
US202163260322P 2021-08-17 2021-08-17
US63/260,322 2021-08-17
US202163261523P 2021-09-23 2021-09-23
US63/261,523 2021-09-23
US202263266535P 2022-01-07 2022-01-07
US63/266,535 2022-01-07
PCT/US2022/016819 WO2022178144A1 (en) 2021-02-17 2022-02-17 Remittive effects of tapinarof in the treatment of plaque psoriasis, atopic dermatitis, or radiation dermatitis

Publications (1)

Publication Number Publication Date
AU2022223701A1 true AU2022223701A1 (en) 2023-09-07

Family

ID=82900200

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022223701A Pending AU2022223701A1 (en) 2021-02-17 2022-02-17 Remittive effects of tapinarof in the treatment of plaque psoriasis, atopic dermatitis, or radiation dermatitis

Country Status (6)

Country Link
US (2) US20240315985A1 (https=)
EP (1) EP4294518A4 (https=)
JP (1) JP2024506953A (https=)
AU (1) AU2022223701A1 (https=)
CA (1) CA3208742A1 (https=)
WO (1) WO2022178144A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11497718B2 (en) 2018-11-13 2022-11-15 Dermavant Sciences GmbH Use of tapinarof for the treatment of atopic dermatitis
JP2025532421A (ja) * 2022-10-10 2025-09-29 上海澤徳曼医薬科技有限公司 潰瘍を予防及び又は治療するためのスチルベン誘導体の使用
WO2024125500A1 (zh) * 2022-12-14 2024-06-20 上海泽德曼医药科技有限公司 一种局部药物组合物及其在医药上的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3297605T (pt) * 2015-05-21 2022-05-30 Dermavant Sciences GmbH Composições farmacêuticas tópicas
US11497718B2 (en) * 2018-11-13 2022-11-15 Dermavant Sciences GmbH Use of tapinarof for the treatment of atopic dermatitis
US20200147000A1 (en) * 2018-11-13 2020-05-14 Dermavant Sciences GmbH Use of tapinarof for the treatment of chronic plaque psoriasis

Also Published As

Publication number Publication date
EP4294518A1 (en) 2023-12-27
WO2022178144A1 (en) 2022-08-25
EP4294518A4 (en) 2025-01-08
JP2024506953A (ja) 2024-02-15
US20240315985A1 (en) 2024-09-26
US20220265572A1 (en) 2022-08-25
CA3208742A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
US20230106782A1 (en) Use of tapinarof for the treatment of chronic plaque psoriasis
US11938099B2 (en) Use of tapinarof for the treatment of atopic dermatitis
US20240315985A1 (en) Remittive effects of tapinarof in the treatment of plaque psoriasis, atopic dermatitis, or radiation dermatitis
US11590138B2 (en) Topical treatment of vitiligo by a jak inhibitor
KR20170139003A (ko) 지방 조직의 저감
JP2014058559A (ja) 局所コエンザイムq10製剤、及び疼痛、疲労、並びに創傷の治療
JP2024506953A5 (https=)
US20220395472A1 (en) Remittive effects of tapinarof in the treatment of plaque psoriasis, atopic dermatitis, or radiation dermatitis
US20230293431A1 (en) Topical treatment of vitiligo by a jak inhibitor
US20260102359A1 (en) Combination treatment of dermal and transdermal fibrotic diseases, disorders and associated pain and inflammation
JPH0971539A (ja) 外用鎮痒剤
KR20260027115A (ko) 타피나로프를 사용하여 아토피 피부염을 치료하는 방법
WO2023165905A1 (en) Composition for treating atopic dermatitis
CA3268830A1 (en) Combination treatment of dermal and transdermal fibrotic diseases, disorders and associated pain and inflammation
EA052074B1 (ru) Топическое лечение витилиго ингибитором jak